The research study was conducted on 06 patients with chronic renal failure who underwent Autologous stem cell treatment (Bone marrow derived stem cells; BM-SC) at Advancells with Informed consents. Before therapy, they were diagnosed with chronic kidney failure with, mean Urea level of 261.66 ± 13.66 mg/dl, a mean Creatinine level of 9.48 ± 2.06 mg/dl, and mean Glomerulation filtration rate (GFR) of 17.0 ± 0.96 ml/min/1.73m2. Four patients were males (66.6%) and two were females (33.3%) with an age range from 25 to 65 years old with a mean of 45.82 ± 13.81, disease duration was between 1 and 03 years. Follow up of the patients after six months of stem cell therapy, the laboratory tests of the patients were calculated to detect any alteration as an effect of this therapy. Thither was a highly significant statistical change in Urea, Creatinine and GFR levels with a mean ±SD of 234.166 ± 19.5 mg/dl, 5.7 ± 2.7 mg/dl and 21.66 ± 1.18 ml/min/1.73m2 respectively (Representative graph for Pre and Post BM-SC Therapy).
Chronic renal failure patients showed promising results that may provide a new hope for those patients suffering from such morbid disease in improving patient's quality of life and leading to less frequent hemodialysis or avoid dialysis.